Skip to main content

Table 1 Characteristics of Subjects

From: Dose-dependent Effect of Statin Therapy on Circulating CXCL12 Levels in Patients with Hyperlipidemia

Characteristic No statin(n=11) Low dose statin(n=48) High dose statin (n=120) p Value
Age (years) 65 +/- 14 64 +/- 11 60 +/- 12 0.489
Male gender 8 (73%) 31 (65%) 85 (71%) 0.707
Race     
Caucasian 11 (100%) 41 (85%) 106 (88%) 0.398
African-American 0 (0%) 7 (15%) 14 (12%) 0.398
Hypertension* 7 (64%) 42 (88%) 104 (87%) 0.098
Diabetes mellitus 4 (36%) 11 (23%) 39 (33%) 0.874
Tobacco use 4 (36%) 10 (21%) 33 (28%) 0.730
Family history of CAD 2 (18%) 23 (48%) 51 (43%) 0.047
Prior Angina 5 (45%) 17 (35%) 55 (46%) 0.802
Peripheral arterial disease 1 (9%) 10 (21%) 33 (28%) 0.460
Congestive heart failure 2 (18%) 3 (6%) 9 (8%) 0.958
Myocardial infarction 3 (27%) 11 (23%) 48 (40%) 0.050
Prior CABG 3 (27%) 4 (8%) 22 (18%) 0.104
Prior PCI 3 (27%) 16 (33%) 47 (40%) 0.401
Prior Stroke 0 (0%) 3 (6%) 18 (15%) 0.445
Medications     
Beta-blocker 7 (64%) 27 (56%) 84 (71%) 0.183
ACE inhibitor 3 (27%) 22 (46%) 53 (45%) 0.397
Aspirin 9 (82%) 36 (75%) 102 (86%) 0.678
Insulin 2 (18%) 5 (10%) 13 (11%) 0.652
Oral hypoglycemic 1 (9%) 7 (15%) 16 (14%) 0.869
Calcium channel blocker 2 (18%) 10 (21%) 15 (13%) 0.681
Clopidogrel 4 (36%) 11 (23%) 30 (25%) 0.393
Lipid panel (mmol/L)     
Total cholesterol 160 [134-161] 157 [136-177] 161 [135-200] 0.593
Low density lipoprotein 88 [81-106] 95 [80-112] 92 [74-131] 0.815
High density lipoprotein 43 [37-51] 38 [33-47] 38 [32-44] 0.128
Triglycerides 89 [55-131] 111 [85-199] 132 [100-194] 0.098
Angiographic data     
Obstructive CAD † 10 (91%) 39 (81%) 106 (88%) 0.434
Non-obstructive CAD 1 (9%) 8 (17%) 19 (16%) 0.819
Presence of collaterals 3 (27%) 16 (67%) 42 (60%) 0.868
Cytokines (pg/mL)     
CXCL1 10516 [2094-27454] 4087 [899-18355] 7709 [1749-20804] 0.026
CXCL3 987 [288-1351] 514 [230-1163] 632 [215-1003] 0.359
CXCL5 5820 [4041-15103] 5127 [2326-8607] 5820 [2985-9245] 0.290
CXCL8 741 [517-1391] 751 [367-1441] 758 [345-1664] 0.884
CXCL9 4133 [68-16835] 3421 [297-7749] 3558 [392-7741] 0.890
CXCL10 1552 [922-2075] 922 [587-1362] 901 [587-1670] 0.117
CXCL11 7577 [2920-9914] 5072 [2711-7724] 4449 [2786-7500] 0.259
CXCL12 2316 [2255-11071] 2362 [2016-10622] 2189 [1968-2705] 0.042
CCL2 131 [32-163] 58 [39-92] 62 [28-132] 0.259
VEGF 909 [559-3997] 1219 [205-1991] 957 [147-1880] 0.678
IFN-γ 472 [92-1034] 317 [113-472] 304 [147-525] 0.467
  1. Data are expressed as mean ± standard deviation (SD), median [25-75% interquartile range (IQR)], or as number (percentage), ACE= angiotensin converting-enzyme, CABG= coronary artery bypass graft surgery, CAD= coronary artery disease, IFN= interferon, PCI= percutaneous coronary intervention, VEGF= vascular endothelial growth factor *= on antihypertensive medications, or untreated patients with known systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg †= ≥70% luminal diameter narrowing of at least one major epicardial artery.